{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:36:47Z","timestamp":1772789807225,"version":"3.50.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2317120","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T05:50:56Z","timestamp":1707457856000},"page":"348-358","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with\n                    <i>RET<\/i>\n                    -altered solid tumors in the US"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-8021","authenticated-orcid":false,"given":"Naleen Raj","family":"Bhandari","sequence":"first","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne M.","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Myers","sequence":"additional","affiliation":[{"name":"Medical Decision Modeling Inc","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Ale-Ali","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-8945","authenticated-orcid":false,"given":"Lee","family":"Smolen","sequence":"additional","affiliation":[{"name":"Medical Decision Modeling Inc","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"e_1_3_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.10.015"},{"key":"e_1_3_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.009"},{"key":"e_1_3_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.01.011"},{"key":"e_1_3_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00328-3"},{"key":"e_1_3_13_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02285"},{"key":"e_1_3_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0593-y"},{"key":"e_1_3_13_9_1","first-page":"10A","article-title":"Challenges estimating the economic value of tissue-agnostic anti-cancer treatments","volume":"24","author":"Sullivan S","year":"2018","unstructured":"Sullivan S, Carlson J, Hansen R, et\u00a0al. Challenges estimating the economic value of tissue-agnostic anti-cancer treatments. J Manag Care Spec Pharm. 2018;24:10A\u201332.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_13_10_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0141"},{"key":"e_1_3_13_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1679"},{"key":"e_1_3_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14082"},{"key":"e_1_3_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11040424"},{"key":"e_1_3_13_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.932353"},{"key":"e_1_3_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101911"},{"key":"e_1_3_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108344"},{"key":"e_1_3_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17791-y"},{"key":"e_1_3_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00347-2"},{"key":"e_1_3_13_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.3106"},{"key":"e_1_3_13_20_1","unstructured":"FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions. 2020 [cited 2023 Jun 9]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions"},{"key":"e_1_3_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653"},{"key":"e_1_3_13_22_1","unstructured":"FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors. 2022 [cited 2023 Jun 8]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive-solid-tumors"},{"key":"e_1_3_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1"},{"key":"e_1_3_13_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07714-3"},{"key":"e_1_3_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-021-00119-9"},{"key":"e_1_3_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33690"},{"key":"e_1_3_13_27_1","unstructured":"Bhandari NR Cinfio F Souri S et\u00a0al. Estimation of the population of patients with ret-altered tumors in the United States. Value Health. 2020;3(5);Supple 1. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/intl2020-3182\/99990"},{"key":"e_1_3_13_28_1","unstructured":"Selpercatinib Prescribing Information. 2022 [cited 2023 Jul 24]. Available from: https:\/\/pi.lilly.com\/us\/retevmo-uspi.pdf"},{"key":"e_1_3_13_29_1","unstructured":"GAVRETO Prescribing Information. 2020 [cited 2023 Aug 9]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/214701s000lbl.pdf"},{"key":"e_1_3_13_30_1","unstructured":"IPSOS Oncology Monitor (US). 2021. [cited 2023 Aug 17]. Available from: https:\/\/www.ipsos.com\/"},{"key":"e_1_3_13_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0967"},{"key":"e_1_3_13_32_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Thyroid Carcinoma. Version 4. 2023. [cited 2023 Sep 15]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf"},{"key":"#cr-split#-e_1_3_13_33_1.1","unstructured":"U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Index-all urban consumers U.S medical care 2022 half year value"},{"key":"#cr-split#-e_1_3_13_33_1.2","unstructured":"2022 [cited 2023 Jun 8]. Available from: http:\/\/data.bls.gov\/cgi-bin\/surveymost?cu"},{"key":"e_1_3_13_34_1","unstructured":"[RED BOOK] Micromedex\u00ae 2.0. (electronic version). Truven Health Analytics Greenwood Village Colorado USA; 2022 [cited 2023 Jul 7]. Available from: http:\/\/www.micromedexsolutions.com\/"},{"key":"e_1_3_13_35_1","unstructured":"CMS ASP File. 2022 [cited 2023 Jun 8]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2022-asp-drug-pricing-files"},{"key":"e_1_3_13_36_1","unstructured":"Avalere Health LLC. Chart 4.5: aggregate hospital payment-to-cost ratios for private payers Medicare and Medicaid. Trendwatch Chartbook 2021. American Hospital Association; 2021 [cited 2023 Jul 9]. Available from: https:\/\/www.aha.org\/system\/files\/media\/file\/2020\/10\/TrendwatchChartbook-2020-Appendix.pdf"},{"key":"e_1_3_13_37_1","unstructured":"[HCUP 2022] HCUPnet Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality Rockville MD; [cited 2023 Jun 8]. Available from: https:\/\/hcupnet.ahrq.gov\/. For more information about HCUP data see http:\/\/www.hcup-us.ahrq.gov\/"},{"key":"e_1_3_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00169"},{"key":"e_1_3_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.09.002"},{"key":"e_1_3_13_40_1","unstructured":"Phase 1\/2 Study of the Highly-selective RET Inhibitor. Pralsetinib (BLU-667) in participants with thyroid cancer non-small cell lung cancer and other advanced solid tumors (ARROW). [cited 2023 Oct 26]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03037385"},{"key":"e_1_3_13_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01063-9"},{"key":"e_1_3_13_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.860671"},{"key":"e_1_3_13_43_1","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: thyroid cancer. [cited 2023 Jun 9]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html"},{"key":"e_1_3_13_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_3_13_45_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21308"},{"key":"e_1_3_13_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-023-00166-4"},{"key":"e_1_3_13_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174415"},{"key":"e_1_3_13_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1141314"},{"key":"e_1_3_13_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137"},{"key":"e_1_3_13_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175"},{"key":"e_1_3_13_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457"},{"key":"e_1_3_13_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309719"},{"key":"e_1_3_13_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2245752"},{"key":"e_1_3_13_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1"},{"key":"e_1_3_13_55_1","unstructured":"Genentech withdraws US indication for pralsetinib in advanced or metastatic RET\u2009+\u2009medullary thyroid cancer. [cited 2023 Sep 15]. Available from: https:\/\/www.onclive.com\/view\/genentech-withdraws-us-indication-for-pralsetinib-in-advanced-or-metastatic-ret-medullary-thyroid-cancer"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2317120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:45:50Z","timestamp":1772779550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2317120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2317120"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2317120","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}